Baxdela (delafloxacin) / Menarini, Melinta Therap, Ligand - LARVOL DELTA

Evaluation of in vitro activity of delafloxacin against Staphylococcus aureus MSSA and MRSA isolated from a Brazilian tertiary hospital. (PubMed, Braz J Microbiol) - "Due to the high sensitivity rates found in this study, delafloxacin may be considered as a good therapeutic option for the treatment of S. aureus infections, including MRSA, particularly in skin and soft tissue infections. The IR Biotyper analysis revealed considerable clonal variation among the isolates, enhancing the robustness of the study."

Journal • Preclinical • Infectious Disease

Advances in the diagnosis and management of skin and soft tissue infections. (PubMed, BMJ) - "Management of SSTI includes antibiotics such as penicillin VK, dicloxacillin, or a cephalosporin, while treatment for skin abscess includes incision and drainage, with antibiotics recommended in select patients. While most patients with cellulitis or skin abscess are appropriate for discharge with follow-up, patients with sepsis and those with challenges adhering to therapy, immunosuppression, or failed outpatient therapy should be referred to the emergency department. Novel antibiotics such as tedizolid, delafloxacin, omadacycline, and ceftaroline may be considered in select cases."

Journal • Review • Dermatology • Infectious Disease • Inflammation • Pain • Septic Shock

In vitro activity of delafloxacin against enterococcal isolates from male urinary tract infections and genetic determinants of resistance. (PubMed, Microbiol Spectr) - "DLX showed higher in vitro activity than both levofloxacin and moxifloxacin against E. faecalis, with an MIC50 of 0.06 mg/L, which was 16- and 4-fold lower than those of these two FQs, respectively. The low frequency of in vitro spontaneous resistant mutants and the predominance of GyrA substitutions among mutants suggest a resistance driven by target modification. Together, these results identify DLX as a promising candidate to address an unmet need in the management of male enterococcal UTIs, but further validation in animal models and clinical studies is needed."

Journal • Preclinical • Infectious Disease • Nephrology

Delafloxacin suppresses DEPDC1 expression and induces G2/M arrest in non-small cell lung cancer cells: A drug repurposing study. (PubMed, Smart Mol) - "While these findings identify Delafloxacin as a candidate for repurposing in lung cancer, the observed downregulation of DEPDC1 represents a correlative finding rather than validated direct targeting. This study provides a rationale for further investigation of Delafloxacin in DEPDC1-associated malignancies."

Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • BIRC5 • CCNB2 • CDK1 • DEPDC1 • EGFR • KIF2C • PLEK • RAS

Some Newer Antibiotics Active Against Helicobacter pylori and Anaerobic Bacteria and the Potential Benefits of Their Wider Availability in More Countries: A Narrative Review. (PubMed, Antibiotics (Basel)) - "Given the limited number of antibiotics for treating CDI and fidaxomicin nonavailability in many countries, it is necessary to conduct more extensive laboratory and clinical studies of promising antibiotics such as ibezapolstat, delafloxacin, lascufloxacin, omadacycline, eravacycline, ridinilazole, and CRS3123...Research on rifasutenizol for bacterial vaginosis, sarecycline and nadifloxacin for acne vulgaris and amixicile for periodontal diseases needs to be expanded. For H. pylori infection, delafloxacin, sitafloxacin, nemonoxacin, zoliflodacin, and rifasutenizol may improve the suboptimal success of most eradication regimens...Establishing more research groups, careful examination of market issues, and additional approaches, such as nanomaterials, efflux pump inhibitors, phage therapy, and CRISPR-Cas systems, should be beneficial. Notwithstanding the difficulties, there are many opportunities to promote research on and potential use of newer antibiotics which show..."

Journal • Review • Acne Vulgaris • Dental Disorders • Dermatology • Infectious Disease • Periodontitis • Vaginitis

Streptococcus pneumoniae: Pathogenesis, virulence factors, antimicrobial resistance mechanisms, and therapeutic strategies. (PubMed, Diagn Microbiol Infect Dis) - "S. pneumoniae functions as an integrated adaptive system rather than a pathogen with independent resistance and evasion mechanisms. Iterative vaccine reformulation is approaching diminishing returns without parallel investment in serotype-independent protein vaccines and whole-genome sequencing surveillance. The mismatch between surveillance infrastructure in high-income countries and LMIC settings, where the greatest burden is concentrated, represents a structural inequity limiting global applicability of current policies. Priority areas include expansion of genomic surveillance to LMIC settings, clinical trials with mucosal protection endpoints for protein vaccine candidates, and explicit development of therapeutics with demonstrated cerebrospinal fluid penetration against multidrug-resistant pneumococci."

Journal • Review • CNS Disorders • Infectious Disease • Otorhinolaryngology • Pneumococcal Infections • Pneumonia • Respiratory Diseases • CD31 • PECAM1

Delafloxacin-induced fever in a patient with staphylococcal periprosthetic joint infection. (PubMed, Int J Antimicrob Agents) - No abstract available

Journal • Infectious Disease

Novel Antibiotics and Emerging Resistance: In Vitro Activity of Five Antimicrobials Against Intensive Care Unit Isolates from a Turkish Tertiary Care Hospital. (PubMed, Infect Dis Clin Microbiol) - "Recently developed antibiotics-ceftazidime-avibactam (CAZ-AVI), ceftolozane-tazobactam (TOL-TAZ), meropenem-vaborbactam (MER-VAB), eravacycline (ERV), and delafloxacin (DLX)-represent promising therapeutic alternatives...Antimicrobial susceptibility testing was conducted with the VITEK® 2 AST XN21 card (bioMérieux, Marcy-l'Étoile, France), while colistin (COL) susceptibility was determined by broth microdilution...Although novel β-lactam/β-lactamase inhibitor combinations expand therapeutic options against multidrug-resistant Gram-negative infections, high resistance rates-particularly among K. pneumoniae isolates-remain concerning. This large-scale study from Türkiye, which provides MIC-based data on five novel agents, highlights the importance of continuous surveillance and rational antibiotic use to preserve their efficacy."

Journal • Preclinical • Critical care • Infectious Disease • Pneumonia

A Quality-by-Design Approach Based Formulation, Optimization, In Vitro and Ex Vivo Evaluation of Delafloxacin-Loaded Ethosomal Gel. (PubMed, AAPS PharmSciTech) - "The ex vivo studies results showed that the ETHs formulation significantly improved drug permeation relative to the free DFX. The results demonstrate that ethosomal gel systems are a potential and safe carrier for the topical application of DFX, offering improved antibacterial efficacy against bacterial skin infections."

Journal • Preclinical • Acne Vulgaris • Dermatology • Infectious Disease

UK Antimicrobial Registry: Virtual Registry-an innovative surveillance approach for monitoring the real-world use and effectiveness of newly licensed antimicrobials in Scotland. (PubMed, JAC Antimicrob Resist) - "Adults (≥18 years) prescribed any of 11 RLAs (cefiderocol, ceftazidime/avibactam, ceftolozane/tazobactam, meropenem/vaborbactam, imipenem/cilastatin/relebactam, eravacycline, ceftaroline, ceftobiprole, dalbavancin, delafloxacin, oritavancin) between June 2019 and June 2023 were included. UKAR:V shows that linked electronic data can support real-world RLA surveillance. With appropriate data linkage, this model offers a scalable, low-burden approach to monitoring utilization/outcomes providing a sustainable foundation for stewardship/policy and assessment of innovative reimbursement models."

Journal • Real-world evidence • Infectious Disease • Pneumonia • Septic Shock

Disproportionality Analysis of Fluoroquinolone-Associated Peripheral Neuropathy in the FAERS Database (2007-2024). (PubMed, Clin Transl Sci) - "Positive disproportionality signals were observed for the commonly prescribed FQs (ciprofloxacin, levofloxacin, moxifloxacin, and ofloxacin), with seven distinct PN manifestations generating signals. Notably, we detected PN-related signals for gemifloxacin, a relatively new FQ with limited prior evaluation of neurotoxicity...Strengthened clinical monitoring for early signs of PN is advisable when FQ treatment becomes unavoidable. Further controlled epidemiological studies are needed to validate these signals and define at-risk groups, alongside mechanistic research aimed at supporting the development of neuroprotective strategies."

Journal • Infectious Disease • Pain

In vitro activity of eravacycline against anaerobic bacteria isolated from clinically significant samples. (PubMed, Enferm Infecc Microbiol Clin (Engl Ed)) - "With some exceptions, the present results show lower MICs for eravacycline in comparison to the other antibiotics used against anaerobes."

Clinical • Journal • Preclinical • Infectious Disease

Evaluating the efficacy of delafloxacin and combination therapy against Staphylococcus aureus Biofilms: insights into activity in acidic environments. (PubMed, Sci Rep) - No abstract available

Journal

SHORTEN-II: Efficacy and safety of 7 versus 14 days of antibiotic treatment for bacteremia produced by Pseudomonas aeruginosa: a multicenter, randomized (SHORTEN-2) clinical trial with a DOOR/RADAR analysis. (clinicaltrialsregister.eu) - P4 | N=306 | Recruiting | Sponsor: Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud De Sevilla | Not yet recruiting ➔ Recruiting

Enrollment open

Temocillin: a therapeutic alternative in bone and joint infections due to third generation cephalosporin-resistant Enterobacterales? (PubMed, J Antimicrob Chemother) - "This study demonstrated the high in vitro efficacy of temocillin against 3GC-R Enterobacterales from BJIs, regardless of the underlying resistance mechanism. However, dosage adjustments based on the strain's MIC and the patient's renal function are crucial for optimal efficacy."

Journal • Infectious Disease

Real-world effectiveness and safety of delafloxacin for the treatment of bacterial infections in adults: results from the early-DELA study (ESCMID Global 2026) - No abstract available

Clinical • Late-breaking abstract • Real-world • Real-world effectiveness • Real-world evidence • Infectious Disease

pH-dependent resistance evolution of delafloxacin (DLX) and ciprofloxacin (CIP) in Pseudomonas aeruginosa from cystic fibrosis (CF) and non-CF patients (ESCMID Global 2026) - No abstract available

Clinical • Cystic Fibrosis • Genetic Disorders • Immunology • Respiratory Diseases

Unraveling ciprofloxacin and delafloxacin efficacy and resistance evolution at multiple concentrations on Pseudomonas aeruginosa infection dynamics; results from a human bronchial epithelium model (ESCMID Global 2026) - No abstract available

Clinical • Infectious Disease

Comparative activity of delafloxacin and linezolid against methicillin-resistant Staphylococcus aureus (MRSA) biofilm: results of an in vitro dynamic model (ESCMID Global 2026) - No abstract available

Preclinical • Infectious Disease

Delafloxacin beyond the label: early clinical experience against fluoroquinolone-resistant infections (ESCMID Global 2026) - No abstract available

Clinical • Infectious Disease

In vitro activity of delafloxacin vs ciprofloxacin, levofloxacin and moxifloxacin against MRSA (ESCMID Global 2026) - No abstract available

Preclinical

Activity of ciprofloxacin vs delafloxacin in acidic environments: impact of SOS response inactivation in Escherichia coli (ESCMID Global 2026) - No abstract available

IPT14 - Fluoroquinolones: friends or foes? One size does not fit all (ESCMID Global 2026) - "Expert speakers will review key clinical data, illustrating its performance alongside a discussion of its safety profile, particularly regarding traditional fluoroquinolones. Attendees will gain a clear, evidence-based understanding of how delafloxacin differentiates from other FQs and its potential role in the treatment of ABSSSI."

Infectious Disease

Efficacy and safety of delafloxacin for musculoskeletal infections caused by levofloxacin-resistant Staphylococci: experience from a multi-centre cohort (ESCMID Global 2026) - No abstract available

Clinical • Infectious Disease • Musculoskeletal Diseases

Model-integrated evidence for delafloxacin: minimal PBPK simulations and network meta-analysis to support urinary tract infection indication development (ESCMID Global 2026) - No abstract available

Retrospective data • Infectious Disease • Nephrology